In 50,845 SEER patients aged ≥70 years with stage I ER-positive breast cancer after BCS, radiation omission was not associated with inferior BCSS (aHR, 0.95; 95% CI, 0.87-1.04), though radiation conferred modest OS benefit, supporting selective de-escalation in older patients.
Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.
Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.
